Vault Quality en Vault RIM-toepassingen automatiseren workflows voor volledig inzicht in verandering controleprocessen en snellere productontwikkeling

BARCELONA, Spanje– (BUSINESS WIRE) – Veeva Systems (NYSE: VEEV) heeft vandaag aangekondigd dat Epredia, een wereldleider op het gebied van precisiekanker en weefseldiagnostiek, de toepassingen Veeva Vault Quality en Veeva Vault RIM overneemt om de controle over veranderingen tussen kwaliteitsmanagement en regelgeving te automatiseren operaties. Veeva MedTech-oplossingen brengen kwaliteits- en regelgevingsinformatie samen op één platform voor meer transparantie tussen processen en naleving van veranderende regelgeving. Nu kan Epredia het beheer van wijzigingen verenigen om de samenwerking te versterken en de productlevenscyclus te versnellen.

Epredia Adopts Veeva MedTech Solutions to Unify Change Control Across Quality and Regulatory

Vault Quality and Vault RIM applications automate workflows for full visibility into change control processes and faster product development

BARCELONA, Spain–(BUSINESS WIRE)– Veeva Systems (NYSE: VEEV) today announced that Epredia, a global leader in precision cancer and tissue diagnostics, is adopting Veeva Vault Quality and Veeva Vault RIM applications to automate change control between quality management and regulatory operations. Veeva MedTech solutions bring together quality and regulatory information on one platform for better transparency across processes and compliance with changing regulations. Now Epredia can unify change control to strengthen collaboration and speed the product lifecycle.

“Veeva MedTech solutions harmonize our global quality assurance and regulatory affairs processes with a single source of content and data,” said Mark Ramser, senior director of global quality at Epredia. “With complete visibility throughout our change management processes, we can make more informed decisions and get products to market much faster.”

Vault Quality and Vault RIM seamlessly connect change control processes to reduce manual overhead and minimize risk of errors. Changes to approved products, manufacturers, and suppliers are managed from end-to-end to better meet diagnostic reporting and visibility requirements, including 21 CFR part 820, ISO13485, and IVDR. Vault Quality handles change control strategies, decisions, and quality document management, while Vault RIM streamlines decision and impact analysis, submission planning and tracking, and document authoring and archiving.

“There is a significant opportunity for MedTech companies to improve how teams across functions work together,” said Jim Diefenbach, general manager of Veeva MedTech. “Epredia is modernizing quality and regulatory processes to simplify the end-to-end workflow for managing product changes and accelerate the total product lifecycle.”

Epredia is adopting regulatory applications Vault Submissions and Vault Submissions Archive, and quality applications Vault QMS, Vault QualityDocs, and Vault Training. Vault Quality and Vault RIM are part of Veeva MedTech, unified suites of cloud applications to manage regulated content and data throughout product development.

Watch the on-demand Veeva MedTech Summit session at veeva.com/MedTechSummit to learn how Epredia is streamlining quality and regulatory processes.

Additional Information

For more on Veeva MedTech, visit: veeva.com/MedTech
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2021 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.

Veeva Systems Inc. owns other registered and unregistered trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005111/en/

Contacts

Roger Villareal

Veeva Systems

925-264-8885

roger.villareal@veeva.com

Deivis Mercado

Veeva Systems

925-226-8821

deivis.mercado@veeva.com